

The Ciprofloxacin Impact on Biofilm Formation by *Proteus Mirabilis* and *P. Vulgaris* Strains

Joanna Kwiecinska-Pirog,¹ Krzysztof Skowron,^{1,*} Wojciech Bartczak,¹ and Eugenia Gospodarek-Komkowska¹

¹Department of Microbiology, Faculty of Pharmacy, Nicolaus Copernicus University in Torun, Collegium Medicum of L. Rydygier in Bydgoszcz, Bydgoszcz, Poland

*Corresponding author: Krzysztof Skowron, Department of Microbiology, Faculty of Pharmacy, Nicolaus Copernicus University in Torun, Collegium Medicum of L. Rydygier in Bydgoszcz, Bydgoszcz, Poland. Tel/Fax: +48-525854047, E-mail: skowron238@wp.pl

Received 2015 August 27; Revised 2015 December 23; Accepted 2016 January 29.

Abstract

Background: *Proteus* spp. bacilli belong to opportunistic human pathogens, which are primarily responsible for urinary tract and wound infections. An important virulence factor is their ability to form biofilms that greatly reduce the effectiveness of antibiotics in the site of infection.

Objectives: The aim of this study was to determine the value of the minimum concentration of ciprofloxacin that eradicates a biofilm of *Proteus* spp. strains.

Materials and Methods: A biofilm formation of 20 strains of *P. mirabilis* and 20 strains of *P. vulgaris* were evaluated by a spectrophotometric method using 0.1% 2, 3, 5-Triphenyl-tetrazolium chloride solution (TTC, AVANTORTM). On the basis of the results of the absorbance of the formazan, a degree of reduction of biofilm and minimum biofilm eradication (MBE) values of MBE50 and MBE90 were determined.

Results: All tested strains formed a biofilm. A value of 1.0 µg/mL ciprofloxacin is MBE50 for the strains of both tested species. An MBE90 value of ciprofloxacin for isolates of *P. vulgaris* was 2 µg/mL and for *P. mirabilis* was 512 µg/mL.

Conclusions: Minimum biofilm eradication values of ciprofloxacin obtained in the study are close to the values of the minimal inhibition concentration (MIC).

Keywords: Biofilm, Ciprofloxacin, *Proteus* spp

1. Background

Bacteria of the genus *Proteus* are Gram-negative rods belonging to the family *Enterobacteriaceae* (1). *Proteus* spp. currently include four named species: *Proteus mirabilis*, *P. vulgaris*, *P. hauseri*, and *P. penneri*, all of which are pathogenic for humans (1). A characteristic feature of *Proteus* spp. rods is the presence of cilia, which increases their virulence, the phenomenon of swarming growth, and the ability to produce urease (2). *Proteus* spp. bacteria mainly are found in water, soil, and natural fertilizers, as well as in food products. These microorganisms also may be present in humans and animals, mainly in the gastrointestinal tract (2).

Urinary tract infections (UTI) are one of the most common infectious diseases, especially in a hospital environment (3). The participation of *P. mirabilis* bacteria in the etiology of UTI is 7%. One of the consequences of UTI caused by *Proteus* spp. may be the formation of kidney stones (2). The microorganisms of the genus *Proteus* also can cause skin and subcutaneous tissue infections as well as infections arising in the case of hernia plastic surgery or acute oti-

tis media, and the microorganisms of the genus *P. mirabilis* can cause purulent meningitis in newborns (2, 4, 5).

Proteus mirabilis and *P. vulgaris* rods have a number of virulence factors, for example, lipopolysaccharide (LPS), flagella, fimbriae, glycocalyx, and the phenomenon of adhesion and hydrophobicity of bacteria surface (2). An important adaptation of the bacteria *Proteus* spp., to cause infections in the urinary system, is the ability to form a biofilm. A biofilm is a formation of communicating microorganisms that adhere to certain surfaces and to neighboring cells and are covered with an extracellular matrix (6). It is often formed on catheters and surgical implants (6). The structure of a biofilm provides protection for bacterial cells against adverse environmental factors, including trade disinfectants and antibiotics (7).

2. Objectives

The aim of this study was to assess the degree of a biofilm formation by strains of *P. mirabilis* and *P. vulgaris* and to determine the effect of ciprofloxacin on planktonic cells and on biofilm of studied microorganisms.

3. Materials and Methods

3.1. Characteristics of the Strains

The material for this study consisted of 20 strains of *P. mirabilis* and 20 strains of *P. vulgaris* from the collection of the department of microbiology of the Ludwik Rydygier medical college in Bydgoszcz, Poland, Nicolaus Copernicus University. The strains were isolated from patients treated in the clinics of the Antoni Jurasz university hospital in Bydgoszcz in 2010 - 2014. Most strains (28; 70.0%) were isolated from patients of the department of general surgery and endocrinology (Figure 1). In the case of *P. mirabilis* and *P. vulgaris*, 25.0% (n = 5) were from urine and 75.0% (n = 15) from a wound swab.




Figure 1. The Origin of *Proteus* spp. Strains

3.2. Susceptibility of the *P. mirabilis* and *P. vulgaris* Strains

The strains were examined by the disk diffusion method to piperacillin, amoxicillin with clavulonic acid, piperacillin with tazobactam, cefotaxime, ceftazidime, cefepime, imipenem, amikacin, ciprofloxacin, norfloxacin, and trimethoprim-sulfamethoxazole (Emapol). The results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendation (8).

3.3. Evaluation of Ciprofloxacin MIC Values of Planktonic Cells

In order to determine the minimal inhibition concentration (MIC) of the tested bacteria, the microdilution method in a microtiter plate was used in accordance with the recommendations of the Clinical and Laboratory Standards Institute (CLSI) (9). The growth of bacteria in the presence of ciprofloxacin at concentrations ranging from 0.01 - 128.0 $\mu\text{g}/\text{mL}$ was evaluated in the studies. *Pseudomonas aeruginosa* strain ATCC 27853 was used for the control assays.

The MIC value was read visually by the presence of turbidity of the suspension in the wells of microtiter plates at a given concentration of antibiotic. The results were interpreted on the basis of recommendations introduced by the EUCAST (8). The limit for the minimum inhibitory concentration of ciprofloxacin is $\leq 0.5 \mu\text{g}/\text{mL}$ for susceptible strains. For intermediately susceptible microorganisms, MIC breakpoints fall within the range of 0.5 - 1.0 $\mu\text{g}/\text{mL}$. In the case of strains that have resistance to ciprofloxacin, the limit of MIC is $> 1 \mu\text{g}/\text{mL}$. MIC₅₀ and MIC₉₀ values were calculated on the basis of the obtained values of MIC. To be more precise, the values include ciprofloxacin concentration, at which the growth of 50% and 90% of strains was inhibited.

3.4. Evaluation of Biofilm Formation

A biofilm formation by the strains of *P. mirabilis* and *P. vulgaris* was evaluated based on the method described previously (10) using a 0.1% TTC (2, 3, 5-Triphenyl-tetrazolium chloride solution, AVANTORTM) with modifications. After a 24-hour incubation, the planktonic, nonadsorbed cells were removed from the wells of the microtiter plates. The wells were washed three times with 600 μL sterile distilled water per cell. 100 μL of tryptic soy medium (TSB, Becton Dickinson) and 100 μL of sterile 0.1% TTC solution were added to each cell and incubated. After two hours, the contents of the wells were removed and washed again with distilled water. The formazan was dissolved in 200 μL methanol (AVANTORTM). The contents of the wells were transferred to sterile microtiter plates. An absorbance measurement was made using a BIO-TEK spectrophotometer at a wavelength of 470 nm. The KC4TM v3.4 and KC4TM Signature program was used to read the data.

The results were interpreted in accordance with the criteria described in the previous publication (10). The obtained results were compared by the Mann-Whitney U test, with differences at $p \leq 0.05$ considered as statistically significant using the StatSoft Inc. (2011) STATISTICA 10.0 program (data analysis software system).

3.5. Assessment of the Ciprofloxacin Influence on *P. mirabilis* and *P. vulgaris* Biofilms

The study evaluated the influence of ciprofloxacin on the 24-hour biofilm of *P. mirabilis* and *P. vulgaris* by the microdilution method in microtiter plates in accordance with the methodology described in the work of Kwiecinska-Pirog et al. (10). As part of the experiment, the minimum biofilm eradication (MBE) values of MBE₅₀ and MBE₉₀ were rated. Those values denote the concentration of antibiotic that leads to an inhibition of biofilm formation by *P. vulgaris* and *P. mirabilis*, respectively, $\geq 50.0\%$ and $\geq 90.0\%$ of the tested strains.

The reduction of the biofilm was determined by a calculation that uses the absorbance values of the tested strains. These values have been registered with a spectrophotometer. The absorbance values of the positive control sample and the average value of the results of the absorbance of the tested strains were used for calculation. The degree of reduction was calculated using the following Equation:

$$\text{Biofilm Reduction Ratio} = \frac{(x - y)}{x} \times 100\% \quad (1)$$

x, absorbance value of positive control; y, absorbance value of the examined strain.

4. Results

4.1. Susceptibility of the *P. mirabilis* and *P. vulgaris* Strains

All examined strains were susceptible to piperacillin with tazobactam, cephalosporines, imipenem, ciprofloxacin, and norfloxacin. One *P. vulgaris* strain (5.0%) was resistant to piperacillin. Five *Proteus* spp. strains (12.5%) were resistant to amoxicillin with clavulonic acid (4, 20.0% of *P. mirabilis*, and 1, 5.0% of *P. vulgaris*). One strain of *P. mirabilis* (5.0%) was resistant to amikacin. Five strains of *P. mirabilis* (25.0%) and one of *P. vulgaris* (5.0%) were resistant to trimethoprim-sulfamethoxazole. The MIC90 value of ciprofloxacin in the case of strains of *P. mirabilis* and *P. vulgaris* isolated from a wound swab was 0.5 µg/mL. The value of the isolates from the urine was equal to 1.0 µg/mL and 0.25 µg/mL, respectively, for *P. mirabilis* and *P. vulgaris* (Table 2).

4.2. The assessment of the Impact of Ciprofloxacin on Planktonic Cells

All tested strains of *P. mirabilis* and *P. vulgaris* were susceptible to ciprofloxacin. However, among the 20 strains of *P. mirabilis* three (15.0%) were classified as the intermediate group. Ciprofloxacin-intermediate strains were isolated from urine. The MIC values of ciprofloxacin for planktonic bacteria cells of both tested species are presented in Table 1. The MIC50 ciprofloxacin values for planktonic cells of *P. mirabilis* and *P. vulgaris* strains were 0.06 µg/mL for both isolates from the wound swabs and those from urine (Table 2).

4.3. Evaluation of Biofilm Formation

All tested strains formed a biofilm. The absorbance value measured for the strains of *P. mirabilis* was in the range of 0.656 - 2.319, while *P. vulgaris* was within the range of 0.708 - 1.800. According to the criteria (10), none of the strains formed a biofilm in a weak degree. In the case

of two tested species, most strains formed a biofilm of medium intensity 12 (60.0%) isolates of *P. mirabilis* and 11 (55.0%) of *P. vulgaris*. Strong biofilm formation was observed for eight (40.0%) strains of *P. mirabilis* and nine strains (45.0%) of *P. vulgaris* (Table 3).

4.4. Assessment of the Impact of Ciprofloxacin on *P. mirabilis* and *P. vulgaris* Biofilms

The MBE50 value of ciprofloxacin was 1.0 µg/mL for the strains of both examined species (Table 4). This value was 16 times higher than the MIC50 for planktonic cells. The MBE90 value of ciprofloxacin for isolates of *P. vulgaris* was 64 µg/mL, and 512 µg/mL for *P. mirabilis* strains (Table 2). The MBE90 value was 512 and 128 times higher than MIC90, respectively, for *P. mirabilis* and for *P. vulgaris*. MBE90 and MBE50 values of ciprofloxacin, depending on clinical material as well as the tested species, are presented in Table 2. No statistically significant difference was observed in resistance of the biofilm formed by *P. mirabilis* and *P. vulgaris* strains ($P = 0.2315$) and by strains isolated from urine and from wound swabs ($P = 0.6335$).

Based on the results of spectrophotometric study, the degree of the reduction of the biofilm of both tested strains was determined (Tables 5 - 6). Only one out of five (20.0%) *P. mirabilis* strains isolated from urine had a biofilm reduction ratio of over 50% at the lowest tested concentration of ciprofloxacin (0.06 µg/mL). Among the strains of the species isolated from the wound swabs, a degree of reduction above 50% for the concentration of 0.06 µg/mL of the tested antibiotic was observed in the case of eight strains (53.3%). For strains of *P. vulgaris*, there was no difference in the degree of reduction of the biofilm at the lowest tested concentrations of ciprofloxacin, depending on the isolation of the strain. The concentration of 0.06 µg/mL resulted in a reduction of more than 50% of the *P. vulgaris* biofilm among as many as 60% of the tested strains.

5. Discussion

In our study, we evaluated the sensitivity of planktonic forms to ciprofloxacin. It was shown that all tested strains of two species of *Proteus* spp., except three isolates (15.0%) of *P. mirabilis* coming from urine, were sensitive to this chemotherapeutic agent. This is consistent with results obtained by other researchers (11-18). Among the 80 strains of *P. mirabilis* analyzed by Saito isolated from urine, 13 (16.0%) were resistant to ciprofloxacin (16). This percentage of resistance strains is similar with results obtained by Hernandez et al. (13) and by Ko et al. (14), who indicated that 16.2% and 13.6%, respectively, of strains were resistant to ciprofloxacin.

Table 1. MIC Value of Ciprofloxacin for *Proteus mirabilis* and *Proteus vulgaris* Strains^a

MIC, µg/mL	<i>Proteus mirabilis</i>		<i>Proteus vulgaris</i>	
	Strains	Cumulated Value	Strains	Cumulated Value
0.01	2 (10.0)	2 (10.0)	2 (10.0)	2 (10.0)
0.03	5 (25.0)	7 (35.0)	5 (25.0)	7 (35.0)
0.06	5 (25.0)	12 (60.0)	6 (30.0)	13 (65.0)
0.12	2 (10.0)	14 (70.0)	1 (5.0)	14 (70.0)
0.25	1 (5.0)	15 (75.0)	3 (15.0)	17 (85.0)
0.50	2 (10.0)	17 (85.0)	3 (15.0)	20 (100.0)
1.00	3 (15.0)	20 (100)	0 (0.0)	20 (100.0)

^aValues are expressed as No. (%) unless otherwise indicated.

Table 2. MIC₅₀, MIC₉₀, MBE₅₀, and MBE₉₀ Values of Ciprofloxacin for *Proteus mirabilis* and *Proteus vulgaris* Strains^a

Parameter	<i>Proteus mirabilis</i>			<i>Proteus vulgaris</i>		
	Wound swab	Urine	All Strains	Wound swab	Urine	All Strains
MIC ₅₀	0.06	0.06	0.06	0.06	0.06	0.06
MIC ₉₀	0.5	1.0	1.0	0.5	0.25	0.5
MBE ₅₀	1.0	4.0	1.0	1.0	0.25	1.0
MBE ₉₀	256.0	512.0	512.0	4.0	2.0	64.0

^aValues are expressed as µg/mL.

Table 3. Biofilm Formation by *Proteus* spp. rods^a

Biofilm Formation	<i>Proteus mirabilis</i>		<i>Proteus vulgaris</i>		Total
	Wound swab	Urine	Wound swab	Urine	
Lack	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Weak	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Moderate	10 (50.0)	2 (10.0)	7 (35.0)	4 (20.0)	23 (57.5)
Strong	5 (25.0)	3 (15.0)	8 (40.0)	1 (5.0)	17 (42.5)
Total	15 (37.5)	5 (12.5)	15 (37.5)	5 (12.5)	40 (100.0)

^aValues are expressed as No. (%).

The presented studies determined that some strains intermediate to ciprofloxacin were among the strains isolated from urine, and all strains isolated from the wound swabs were susceptible to this antibiotic. According to Guggenheim et al. (12), 100% of wound-swab-derived strains of *Proteus* spp. were susceptible to ciprofloxacin. Yah et al. (18) obtained a lower percentage (5.2%) of *P. mirabilis* strains from wound swabs that were resistant to that antibiotic. According to Gales et al. (11), 18.5% of *P. mirabilis* strains isolated from urine were resistant to ciprofloxacin. Wagenlehner et al. (17) determined that

0% - 11.6% of *Proteus* spp. strains isolated from urine between 1994 and 2000 were resistant to ciprofloxacin. In contrast, Abdi-Ali et al. (19) found that *Acinetobacter baumannii* isolated from urinary catheters were less resistant to the ciprofloxacin than those isolated from wounds.

Saito et al. (16) also drew attention to a clear increase in the incidence of *P. mirabilis* infections' resistance to broad-spectrum fluoroquinolones and cephalosporins. According to the study of Kanayama et al. (20), 74.2% ESBL-positive strains were nonsusceptible to ciprofloxacin, whereas only 17.7% of the ESBL-negative strains were. The presence of

Table 4. MBE Value of Ciprofloxacin for *Proteus mirabilis* and *Proteus vulgaris* Biofilm^a

MBE, µg/mL	<i>Proteus mirabilis</i>		<i>Proteus vulgaris</i>	
	Strains	Cumulated Value	Strains	Cumulated Value
0.06	1 (5.0)	1 (5.0)	2 (10.0)	2 (10.0)
0.12	1 (5.0)	2 (10.0)	1 (5.0)	3 (15.0)
0.25	1 (5.0)	3 (15.0)	4 (20.0)	7 (35.0)
0.5	4 (20.0)	7 (35.0)	2 (10)	9 (45.0)
1.0	3 (15.0)	10 (50.0)	4 (20.0)	13 (65.0)
2.0	0 (0.0)	10 (50.0)	0 (0.0)	13 (65.0)
4.0	3 (15.0)	13 (65.0)	3 (15.0)	16 (65.0)
8.0	2 (10.0)	15 (75.0)	0 (0.0)	16 (65.0)
16.0	0 (0.0)	15 (75.0)	0 (0.0)	16 (65.0)
32.0	0 (0.0)	15 (75.0)	1 (5.0)	17 (70.0)
64.0	0 (0.0)	15 (75.0)	2 (10.0)	19 (95.0)
125.0	1 (5.0)	16 (80.0)	0 (0.0)	19 (95.0)
256.0	1 (5.0)	17 (85.0)	0 (0.0)	19 (95.0)
512.0	2 (10.0)	19 (95.0)	0 (0.0)	19 (95.0)
> 512.0	1 (5.0)	20 (100.0)	1 (5.0)	20 (100.0)

^aValues are expressed as No. (%).

Table 5. The Percentages of Reduction of Biofilm Formed by *Proteus mirabilis* and *Proteus vulgaris* Strains Isolated From the Urine

Ciprofloxacin Concentration, µg/mL	<i>Proteus mirabilis</i>					<i>Proteus vulgaris</i>				
	1	2	3	4	5	1	2	3	4	5
512.0	93	95	95	95	90	95	94	96	93	88
256.0	95	93	93	93	> 50	95	93	95	95	91
128.0	92	91	91	92	> 50	96	94	95	89	92
64.0	92	93	93	95	> 50	95	88	96	94	91
32.0	94	93	93	94	> 50	95	87	95	91	91
16.0	94	92	92	94	> 50	95	93	95	> 50	91
8.0	95	90	90	94	> 50	95	94	95	> 50	90
4.0	94	93	93	93	< 50	95	76	96	> 50	91
2.0	95	> 50	> 50	> 50	< 50	95	80	96	> 50	86
1.0	89	< 50	< 50	< 50	< 50	69	87	95	> 50	93
0.5	94	< 50	< 50	< 50	< 50	94	95	95	> 50	91
0.25	95	< 50	< 50	< 50	< 50	95	92	69	< 50	58
0.125	> 50	< 50	< 50	< 50	< 50	> 50	> 50	90	< 50	83
0.06	> 50	< 50	< 50	< 50	< 50	< 50	> 50	92	< 50	64

ESBL among these strains can be explained by previous usage of fluoroquinolones. Saito *et al.* (16) also note that seven (9.0%) resistant strains were isolated from patients previously treated with antibiotics. In this study, the presence of strains intermediate to ciprofloxacin among strains delivered from urine can be caused by earlier treatment of UTI with fluoroquinolones, recommended in Poland.

A very important factor that reduces the effectiveness of antibiotics on bacterial cells is the formation of a biofilm. The strains able to form a strong biofilm can have a high level of resistance to antibiotics related to the presence of genes involved in resistance mechanisms (21). Studies have shown that all strains of *P. vulgaris* and *P. mirabilis*, regardless of the clinical material from which they were isolated, form a biofilm. This is consistent with the liter-

Table 6. The Percentages of Reduction of Biofilm Formed by *Proteus mirabilis* and *Proteus vulgaris* Strains Isolated From the Wound Swabs

Ciprofloxacin Concentration, µg/ml	Biofilm Reduction of Strains, %														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
<i>Proteus mirabilis</i>															
512.0	95	91	92	94	96	90	94	95	90	96	94	84	> 50	86	88
256.0	93	92	93	95	92	93	87	94	> 50	94	86	87	> 50	92	89
128.0	94	94	93	92	92	92	> 50	95	> 50	88	90	91	> 50	90	86
64.0	94	95	94	90	89	92	> 50	94	> 50	86	89	92	> 50	> 50	84
32.0	95	95	92	91	94	91	> 50	94	> 50	90	82	91	> 50	94	85
16.0	95	90	87	91	94	89	> 50	95	> 50	92	92	92	> 50	91	84
8.0	95	95	89	91	90	85	> 50	96	> 50	91	92	92	> 50	90	85
4.0	95	95	91	86	92	88	> 50	94	<50	91	> 50	91	> 50	> 50	> 50
2.0	95	94	91	88	94	91	> 50	96	<50	92	> 50	91	> 50	> 50	> 50
1.0	95	94	90	89	93	87	> 50	95	<50	89	< 50	86	> 50	> 50	> 50
0.5	93	88	91	> 50	> 50	> 50	> 50	88	> 50	86	< 50	87	> 50	> 50	< 50
0.25	> 50	> 50	93	> 50	> 50	> 50	< 50	> 50	< 50	> 50	> 50	91	> 50	> 50	< 50
0.125	> 50	< 50	93	> 50	< 50	> 50	< 50	> 50	< 50	> 50	> 50	93	> 50	> 50	< 50
0.06	< 50	< 50	> 50	> 50	> 50	> 50	< 50	< 50	< 50	> 50	< 50	92	> 50	> 50	< 50
<i>Proteus vulgaris</i>															
512.0	97	96	85	85	87	93	< 50	92	92	79	98	95	91	99	96
256.0	96	96	85	85	84	85	< 50	94	95	80	96	90	92	97	96
128.0	95	95	91	91	87	90	< 50	89	95	93	94	91	> 50	96	96
64.0	96	96	88	88	90	81	< 50	86	95	94	89	85	89	95	95
32.0	97	97	87	87	89	82	< 50	83	96	> 50	> 50	84	89	94	96
16.0	97	97	86	86	89	89	< 50	> 50	95	90	> 50	89	82	95	97
8.0	97	97	92	92	89	93	< 50	> 50	94	96	< 50	87	84	95	97
4.0	96	96	92	92	> 50	89	< 50	> 50	93	93	51	95	85	95	97
2.0	96	96	89	89	82	> 50	< 50	< 50	91	> 50	< 50	89	> 50	86	97
1.0	91	89	92	92	88	> 50	< 50	< 50	95	> 50	< 50	93	> 50	91	97
0.5	96	96	> 50	> 50	92	> 50	< 50	< 50	93	> 50	> 50	> 50	< 50	95	87
0.25	96	96	> 50	> 50	85	> 50	< 50	< 50	> 50	< 50	< 50	< 50	< 50	95	85
0.125	90	> 50	> 50	> 50	82	> 50	< 50	< 50	< 50	< 50	< 50	< 50	< 50	< 50	> 50
0.06	> 50	> 50	> 50	> 50	86	85	< 50	< 50	> 50	< 50	< 50	< 50	< 50	> 50	> 50

ature reports (3, 22-24). Jacobsen et al. (3) proved that all 50 strains of *Proteus* spp., isolated from urinary catheters, form a biofilm. Incubation of the tested strains, as in the case of our research, lasted 12 - 24 hours. In our experiment, it was established that 12 (60.0%) strains belonging to *P. mirabilis* formed a medium biofilm, and eight (40.0%) strains formed a strong biofilm. Among *P. vulgaris* rods were respectively 11 (55.0%) and nine (45.0%) strains. Myszkla et al. (21) received comparable results of their own research. From the 50 strains of *P. vulgaris*, only five (10.0%) were characterized by a poor production of a biofilm, and the remaining 45 (90.0%) formed a strong biofilm (22).

In our study, it was found that the MIC50 and MIC90 values of *Proteus* spp. strains are lower than the MBE50 and MBE90 values. Relatively small differences in MBE and MIC values of ciprofloxacin can be explained by a good penetration of the antibiotic into the biofilm (25). Ciprofloxacin also can decrease bacteria's ability to form biofilm (26). This is confirmed by the results of drug susceptibility of

planktonic cells and biofilm strains of *Klebsiella pneumoniae* obtained by Bellifa et al. (27). Ciprofloxacin compared to cefotaxime and gentamicin has the lowest coefficient values of MBE to MIC (27). Singh also observed no difference in the zones of growth inhibition of biofilm cells and planktonic cells of *S. aureus* and *S. epidermidis* under the influence of ciprofloxacin (28).

Wasfi et al. (29) indicated that the reduction of *P. mirabilis* and *P. vulgaris* biofilm increased with the increase of the concentration of ciprofloxacin. The concentration of 0.5 MIC resulted in the reduction of the biofilm of *P. mirabilis* of 64.0% - 93.0% and a concentration of 0.25 MIC by 28.0% - 91.0%, depending on the strain (29). Similar results for *P. aeruginosa* strains were obtained by Ołdak and Trafny (30). Single application (concerning a 24-hour biofilm) or several times (once every 24 hours from 1-4 nights) at subinhibitory concentrations of ciprofloxacin reduced the biofilm mass. Also, application of ciprofloxacin at a concentration of 0.5 MIC on 24-, 48-,

and 72-hour biofilms of *Escherichia coli* effectively reduces its weight and metabolic activity (31).

In summary, the MBE values of ciprofloxacin are close to the MIC values. The biofilm of *P. mirabilis* strains isolated from urine is more resistant to ciprofloxacin than the biofilm created by strains isolated from wound swabs; however, the differences are not statistically important.

Acknowledgments

This research was supported financially by the Nicolaus Copernicus university with funds from the maintenance of the research potential of the department of microbiology DS-UPB no. 933.

Footnotes

Authors' Contribution: Joanna Kwiecinska-Pirog prepared conception and design of the study, took a part in analysis, interpretation of data, and critical revision of the article for important intellectual content, and provided the study material; Krzysztof Skowron took a part in preparation of study conception, design, and analysis and interpretation of data, and made a statistical analysis of obtained results and critical revision of the article; Wojciech Bartczak made the laboratory part of the experiment, looked for references, and took part in preparation of study conception and design and in analysis and interpretation of data; Eugenia Gospodarek prepared the critical revision of the article for important intellectual content and made the final approval of the study and manuscript.

Financial Disclosure: Authors have no financial interests related to the material.

References

- Manos J, Belas R. The Genera *Proteus*, *Providencia*, and *Morganella*. 2006;245-69. doi: [10.1007/0-387-30746-x_12](https://doi.org/10.1007/0-387-30746-x_12).
- Rozalski A, Kwil I, Torzewska A, Baranowska M, Staczek P. *Proteus* bacilli: features and virulence factors. *Postepy Hig Med Dosw (Online)*. 2007;61:204-19. [PubMed: [17507868](https://pubmed.ncbi.nlm.nih.gov/17507868/)].
- Jacobsen SM, Stickler DJ, Mobley HLT, Shirtliff ME. Complicated Catheter-Associated Urinary Tract Infections Due to *Escherichia coli* and *Proteus mirabilis*. *Clinical Microbiology Reviews*. 2008;21(1):26-59. doi: [10.1128/cmr.00019-07](https://doi.org/10.1128/cmr.00019-07).
- Billewicz-Kraczkowska A, Kulik-Rechberger B, Furmaga-Jablońska W. A noninvasive treatment of multiple brain abscesses in the course of neonatal cerebrospinal meningitis with *Proteus mirabilis* as etiological agent: A case study. *Child Neurology*. 2007;16(31):51-4.
- Reslinski A., Mikucka A., Szczepny W., Szmytkowski J., Gospodarek E., Dabrowiecki S. Wykrywanie biofilmu in vivo na powierzchni siatki chirurgicznej-opis przypadku. *Chir Pol*. 2008;10(1-2):181-8.
- Kokare CR, Chakraborty S, Khopade AN, Mahadik KR. Biofilm: Importance and applications. *Ind J Biotechnology*. 2009;8(2):159-68.
- Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. *Int J Antimicrob Agents*. 2010;35(4):322-32. doi: [10.1016/j.ijantimicag.2009.12.011](https://doi.org/10.1016/j.ijantimicag.2009.12.011).
- European Committee on Antimicrobial Susceptibility Testing. Break-point tables for interpretation of MICs and zone diameters. 2014.
- CLSI. CLSI Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2015.
- Kwiecinska-Pirog J, Skowron K, Zniszczol K, Gospodarek E. The assessment of *Proteus mirabilis* susceptibility to ceftazidime and ciprofloxacin and the impact of these antibiotics at subinhibitory concentrations on *Proteus mirabilis* biofilms. *Biomed Res Int*. 2013;2013:930876. doi: [10.1155/2013/930876](https://doi.org/10.1155/2013/930876). [PubMed: [2451628](https://pubmed.ncbi.nlm.nih.gov/2451628/)].
- Gales AC, Sader HS, Jones RN. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). *Diagnostic Microbiology and Infectious Disease*. 2002;44(3):289-99. doi: [10.1016/s0732-8893\(02\)00470-4](https://doi.org/10.1016/s0732-8893(02)00470-4).
- Guggenheim M, Zbinden R, Handschin AE, Gohritz A, Altintas MA, Giovanoli P. Changes in bacterial isolates from burn wounds and their antibiograms: A 20-year study (1986-2005). *Burns*. 2009;35(4):553-60. doi: [10.1016/j.burns.2008.09.004](https://doi.org/10.1016/j.burns.2008.09.004).
- Hernandez JR, Martinez-Martinez L, Pascual A, Suarez AI, Perea EJ. Trends in the susceptibilities of *Proteus mirabilis* isolates to quinolones. *Journal of Antimicrobial Chemotherapy*. 2000;45(3):407-8. doi: [10.1093/jac/45.3.407](https://doi.org/10.1093/jac/45.3.407).
- Ko KS, Lee MY, Song JH, Lee H, Jung DS, Jung SI, et al. Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Korean hospitals. *Diagn Microbiol Infect Dis*. 2008;61(4):453-9. doi: [10.1016/j.diagmicrobio.2008.03.005](https://doi.org/10.1016/j.diagmicrobio.2008.03.005). [PubMed: [18482815](https://pubmed.ncbi.nlm.nih.gov/18482815/)].
- Sohn KM, Kang C, Joo EJ, Ha YE, Chung DR, Peck KR, et al. Epidemiology of Ciprofloxacin Resistance and Its Relationship to Extended-Spectrum β -Lactamase Production in *Proteus mirabilis* Bacteremia. *Korean J Intern Med*. 2011;26(1):89. doi: [10.3904/kjim.2011.26.1.89](https://doi.org/10.3904/kjim.2011.26.1.89).
- Saito R, Okugawa S, Kumita W, Sato K, Chida T, Okamura N, et al. Clinical epidemiology of ciprofloxacin-resistant *Proteus mirabilis* isolated from urine samples of hospitalised patients. *Clin Microbiol Infect*. 2007;13(12):1204-6. doi: [10.1111/j.1469-0691.2007.01826.x](https://doi.org/10.1111/j.1469-0691.2007.01826.x). [PubMed: [17850340](https://pubmed.ncbi.nlm.nih.gov/17850340/)].
- Wagenlehner FME, Niemetz A, Dalhoff A, Naber KG. Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000. *Int J Antimicrobial Agents*. 2002;19(6):557-64. doi: [10.1016/s0924-8579\(02\)00100-0](https://doi.org/10.1016/s0924-8579(02)00100-0).
- Yah SC, Eghafona NO, Oranus S, Abouo AM. Widespread plasmid resistance genes among *Proteus* species in diabetic wounds of patients in the Ahmadu Bello university teaching hospital (ABUTH) Zaria. *Afr J Biotechnol*. 2007;6(15).
- Abdi-Ali A, Hendiani S, Mohammadi P, Gharavi S. Assessment of Biofilm Formation and Resistance to Imipenem and Ciprofloxacin among Clinical isolates of *Acinetobacter baumannii* in Tehran. *Jundishapur J Microbiol*. 2014;7(1) doi: [10.5812/jjm.8606](https://doi.org/10.5812/jjm.8606).
- Kanayama A, Kobayashi I, Shibuya K. Distribution and antimicrobial susceptibility profile of extended-spectrum beta-lactamase-producing *Proteus mirabilis* strains recently isolated in Japan. *Int J Antimicrob Agents*. 2015;45(2):113-8. doi: [10.1016/j.ijantimicag.2014.06.005](https://doi.org/10.1016/j.ijantimicag.2014.06.005). [PubMed: [25182712](https://pubmed.ncbi.nlm.nih.gov/25182712/)].
- Myszka K, Czaczyk K. Effect of starvation stress on morphological changes and production of adhesive exopolysaccharide (EPS) by *Proteus vulgaris*. *Acta Sci Pol*. 2015;10(3):305-12. doi: [10.5812/jjm.21042](https://doi.org/10.5812/jjm.21042).
- Azizi O, Shakibaie MR, Modarresi F, Shahcheraghi F. Molecular detection of class-D OXA carbapenemase genes in biofilm and non-biofilm forming clinical isolates of *Acinetobacter baumannii*. *Jundishapur J Microbiol*. 2015;8(1):e21042. doi: [10.5812/jjm.21042](https://doi.org/10.5812/jjm.21042).
- Ali OAU. Prevention of *Proteus mirabilis* biofilm by surfactant solution. *Egypt Acad J of Biol Sci*. 2012;4:1-8.

24. Aniejurengho OUV, Dessi M, Meikle S, Santin M, Okoli I. Biofilm formation in uropathogenic strains of *Proteus mirabilis* and their susceptibility to poly (epsilon-lysine) dendron. *Biosci Res Today World*. 2015;**1**(1):1-9.
25. Arabski M, Wasik S, Zych M, Lakomiec W, Kaca W. Analysis of ciprofloxacin and gentamicin diffusion in *Proteus mirabilis* O18 biofilm by laser interferometry method. *Acta Biochim Pol*. 2013;**60**(4):707-11. [PubMed: 24432321].
26. Shafiei M, Abdi Ali A, Shahcheraghi F, Saboora A, Akbari Noghahi K. Eradication of *Pseudomonas aeruginosa* Biofilms Using the Combination of n-butanolic Cyclamen coum Extract and Ciprofloxacin. *Jundishapur J Microbiol*. 2014;**7**(2) doi: 10.5812/jjm.14358.
27. Bellifa S, Hassaine H, Balestrino D, Charbonnel N, M'hamedi I, Terki IK, et al. Evaluation of biofilm formation of *Klebsiella pneumoniae* isolated from medical devices at the University Hospital of Tlemcen, Algeria. *Afr J Microbiol Res*. 2013;**7**(49):5558-64.
28. Singh R, Ray P, Das A, Sharma M. Penetration of antibiotics through *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms. *J Antimicrob Chemother*. 2010;**65**(9):1955-8. doi: 10.1093/jac/dkq257.
29. Wasfi R, Abd El-Rahman OA, Mansour LE, Hanora AS, Hashem AM, Ashour MS. Antimicrobial activities against biofilm formed by *Proteus mirabilis* isolates from wound and urinary tract infections. *Indian J Med Microbiol*. 2012;**30**(1):76-80. doi: 10.4103/0255-0857.93044. [PubMed: 22361765].
30. Oldak E, Trafny EA. Secretion of proteases by *Pseudomonas aeruginosa* biofilms exposed to ciprofloxacin. *Antimicrob Agents Chemother*. 2005;**49**(8):3281-8. doi: 10.1128/AAC.49.8.3281-3288.2005. [PubMed: 16048937].
31. Wojnicz D, Tichaczek-Goska D. Effect of sub-minimum inhibitory concentrations of ciprofloxacin, amikacin and colistin on biofilm formation and virulence factors of *Escherichia coli* planktonic and biofilm forms isolated from human urine. *Braz J Microbiol*. 2013;**44**(1):259-65. doi: 10.1590/S1517-83822013000100037. [PubMed: 24159313].